By: IPP Bureau
Last updated : April 24, 2026 1:56 pm
Veteran pharma leader brings 33+ years of experience to drive operational excellence in formulation business
Shilpa Medicare Limited has appointed Dr Vellaian Karuppiah as its new Chief Operating Officer (COO) – Formulations, effective April 23, 2026, following approval by the Nomination and Remuneration Committee.
The appointment has been disclosed to stock exchanges in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with applicable SEBI circulars.
According to the company’s filing, Dr. Karuppiah will serve as a Senior Managerial Personnel in a full-time capacity, taking charge of the company’s formulations operations.
Dr. Karuppiah brings over 33 years of experience across the pharmaceutical value chain, with expertise spanning formulation and analytical R&D, regulatory affairs, manufacturing science and technology (MS&T), technology transfer, engineering and projects, quality systems, EHS/ESG, supply chain management, PPIC, and end-to-end manufacturing operations.
Most recently, he served as Chief Operating Officer at Acme Group and Immacule Lifesciences, where he was involved in strengthening manufacturing efficiency, supply chain resilience, quality systems, and R&D integration.
The company highlighted that his leadership experience spans both domestic and global markets, with a consistent focus on operational excellence, regulatory compliance, and transformation initiatives.
Dr. Karuppiah holds a postgraduate degree and doctorate in pharmacy, along with executive management qualifications from leading institutions in India and abroad.